“They (Adar and Serum) are trying to fruitfully deploy the large cash pile that the company would have generated from the vaccine sales,” said Vishal Manchanda, research analyst at Systematix ...

"They (Adar and Serum) are trying to fruitfully deploy the large cash pile that the company would have generated from the vaccine sales," said Vishal Manchanda, research analyst at Systematix ...

By Rishika Sadam and Hritam Mukherjee (Reuters) -Adar Poonawalla, CEO of vaccine maker Serum Institute of India, will buy a 50% stake in filmmaker Karan Johar's Dharma Productions for 10 billion ...

"They (Adar and Serum) are trying to fruitfully deploy the large cash pile that the company would have generated from the vaccine sales," said Vishal Manchanda, research analyst at Systematix ...

Vishal Manchanda, Senior Vice-President (Institutional Research) with Systematix Group, observed that the US Biosecure Act (that looks to restrict US companies from working with some Chinese ...

“They (Adar and Serum) are trying to fruitfully deploy the large cash pile that the company would have generated from the vaccine sales,” said Vishal Manchanda, research analyst at Systematix ...

Photo: Reuters/Arnd Wiegmann “They (Adar and Serum) are trying to fruitfully deploy the large cash pile that the company would have generated from the vaccine sales,” said Vishal Manchanda ...

Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen ...

Start learning with the Library's partner in one-on-one tutoring, Brainfuse. Log in with your library card number for access. Please note: library cards must have a ...